Compare ETD & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETD | OCGN |
|---|---|---|
| Founded | 1932 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 474.8M |
| IPO Year | 1996 | 2014 |
| Metric | ETD | OCGN |
|---|---|---|
| Price | $19.99 | $0.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $22.00 | $12.17 |
| AVG Volume (30 Days) | 448.3K | ★ 6.6M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 8.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $766,784,000.00 | N/A |
| Revenue This Year | N/A | $12.33 |
| Revenue Next Year | $2.11 | $10.95 |
| P/E Ratio | $13.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.28 | $0.79 |
| 52 Week High | $28.21 | $2.73 |
| Indicator | ETD | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.49 | 25.85 |
| Support Level | $18.28 | N/A |
| Resistance Level | $22.95 | $1.12 |
| Average True Range (ATR) | 0.46 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 6.08 | 6.24 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").